Cargando…

Correction: Cost-utility and budget impact analyses of the use of NEPA for chemotherapy-induced nausea and vomiting prophylaxis in Italy

Detalles Bibliográficos
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BMJ Publishing Group 2017
Materias:	Miscellaneous
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5770816/ https://www.ncbi.nlm.nih.gov/pubmed/29275353 http://dx.doi.org/10.1136/bmjopen-2016-015645corr1

Ejemplares similares

Cost-utility and budget impact analyses of the use of NEPA for chemotherapy-induced nausea and vomiting prophylaxis in Italy
por: Restelli, Umberto, et al.
Publicado: (2017)

Management of Chemotherapy-Induced Nausea and Vomiting (CINV): A Short Review on the Role of Netupitant-Palonosetron (NEPA)
por: Lorusso, Vito, et al.
Publicado: (2020)

The effectiveness of NEPA in the prevention of chemotherapy-induced nausea vomiting among chemo naive patients in an Indian setting
por: Vaswani, Bharat, et al.
Publicado: (2021)

Netupitant-palonosetron (NEPA) for Preventing Chemotherapy-induced Nausea and Vomiting: From Clinical Trials to Daily Practice
por: Aapro, Matti, et al.
Publicado: (2022)

Timing flexibility of oral NEPA, netupitant-palonosetron combination, administration for the prevention of chemotherapy-induced nausea and vomiting (CINV)
por: Baron-Hay, Sally, et al.
Publicado: (2019)

NEPA, a new fixed combination of netupitant and palonosetron, is a cost-effective intervention for the prevention of chemotherapy-induced nausea and vomiting in the UK
por: Cawston, Helene, et al.
Publicado: (2017)

Single‐dose NEPA versus an aprepitant regimen for prevention of chemotherapy‐induced nausea and vomiting in patients receiving moderately emetogenic chemotherapy
por: Zelek, Laurent, et al.
Publicado: (2023)

Profile of netupitant/palonosetron (NEPA) fixed dose combination and its potential in the treatment of chemotherapy-induced nausea and vomiting (CINV)
por: Navari, Rudolph M
Publicado: (2014)

Preventing chemotherapy-induced nausea and vomiting in patients with lung cancer: efficacy of NEPA (netupitant-palonosetron), the first combination antiemetic
por: Hesketh, Paul J., et al.
Publicado: (2017)

A Pragmatic Study Evaluating NEPA Versus Aprepitant for Prevention of Chemotherapy‐Induced Nausea and Vomiting in Patients Receiving Moderately Emetogenic Chemotherapy
por: Zelek, Laurent, et al.
Publicado: (2021)

Cost-effectiveness of a fixed combination of netupitant and palonosetron (NEPA) relative to aprepitant plus granisetron (APR + GRAN) for prophylaxis of chemotherapy-induced nausea and vomiting (CINV): a trial-based analysis
por: Botteman, Marc, et al.
Publicado: (2019)

Cost-effectiveness analysis of NEPA, a fixed-dose combination of netupitant and palonosetron, for the prevention of highly emetogenic chemotherapy-induced nausea and vomiting: an international perspective
por: Nilsson, Jonas, et al.
Publicado: (2022)

A Review of NEPA, a Novel Fixed Antiemetic Combination with the Potential for Enhancing Guideline Adherence and Improving Control of Chemotherapy-Induced Nausea and Vomiting
por: Hesketh, Paul J., et al.
Publicado: (2015)

Economic Value of Fosaprepitant-Containing Regimen in the Prevention of Chemotherapy-Induced Nausea and Vomiting in China: Cost-Effectiveness and Budget Impact Analysis
por: Xu, Xinglu, et al.
Publicado: (2022)

Adherence to ASCO for Prophylaxis of Acute Chemotherapy-Induced Nausea and Vomiting in Iran
por: Ebrahimi, Mahbobeh, et al.
Publicado: (2020)

Efficacy and safety of NEPA, an oral combination of netupitant and palonosetron, for prevention of chemotherapy-induced nausea and vomiting following highly emetogenic chemotherapy: a randomized dose-ranging pivotal study
por: Hesketh, P. J., et al.
Publicado: (2014)

Chemotherapy-Induced Nausea and Vomiting
por: Rapoport, Bernardo Leon, et al.
Publicado: (2015)

Dextrose for post-operative nausea and vomiting prophylaxis
por: Castro-Alves, Lucas J, et al.
Publicado: (2018)

A phase III study evaluating the safety and efficacy of NEPA, a fixed-dose combination of netupitant and palonosetron, for prevention of chemotherapy-induced nausea and vomiting over repeated cycles of chemotherapy
por: Gralla, R. J., et al.
Publicado: (2014)

Phase IIIb Safety and Efficacy of Intravenous NEPA for Prevention of Chemotherapy‐Induced Nausea and Vomiting (CINV) in Patients with Breast Cancer Receiving Initial and Repeat Cycles of Anthracycline and Cyclophosphamide (AC) Chemotherapy
por: Schwartzberg, Lee, et al.
Publicado: (2019)

The Effectiveness of an Oral Fixed-Dose Combination of Netupitant and Palonosetron (NEPA) in Patients With Multiple Risk Factors for Chemotherapy-Induced Nausea and Vomiting: A Multicenter, Observational Indian Study
por: Vaswani, Bharat, et al.
Publicado: (2022)

Impact of tumour burden on chemotherapy-induced nausea and vomiting.
por: Hursti, T. J., et al.
Publicado: (1996)

The big “little problem” with postoperative nausea and vomiting prophylaxis
por: Chilkoti, G, et al.
Publicado: (2015)

Chemotherapy- and cancer-related nausea and vomiting
por: Warr, D.G.
Publicado: (2008)

A randomized phase III study evaluating the efficacy and safety of NEPA, a fixed-dose combination of netupitant and palonosetron, for prevention of chemotherapy-induced nausea and vomiting following moderately emetogenic chemotherapy
por: Aapro, M., et al.
Publicado: (2014)

A Study on Utilization and Evaluation of Antiemetics in Chemotherapy-induced Nausea and Vomiting
por: Baburaj, Gayathri, et al.
Publicado: (2017)

Differential pharmacology and clinical utility of rolapitant in chemotherapy-induced nausea and vomiting
por: Rapoport, Bernardo Leon
Publicado: (2017)

Standardised electronic algorithms for monitoring prophylaxis of postoperative nausea and vomiting
por: Gillmann, Hans-Jörg, et al.
Publicado: (2019)

Correction to: Netupitant/Palonosetron: A Review in Chemotherapy-Induced Nausea and Vomiting
por: Shirley, Matt
Publicado: (2021)

Management of Patients With Chemotherapy-Induced Nausea and Vomiting
por: Barbour, Sally Yowell
Publicado: (2017)

Chemotherapy-Induced Nausea and Vomiting: Updates and Recommendations
por: Viale, Pamela Hallquist
Publicado: (2018)

Evaluating the impact of chemotherapy-induced nausea and vomiting on daily functioning in patients receiving dexamethasone-sparing antiemetic regimens with NEPA (netupitant/palonosetron) in the cisplatin setting: results from a randomized phase 3 study
por: Celio, Luigi, et al.
Publicado: (2022)

An assessment of chemotherapy-induced nausea and vomiting direct costs in three EU countries
por: Turini, Marco, et al.
Publicado: (2015)

Efficacy and safety of netupitant/palonosetron combination (NEPA) in preventing nausea and vomiting in non-Hodgkin’s lymphoma patients undergoing to chemomobilization before autologous stem cell transplantation
por: Di Renzo, Nicola, et al.
Publicado: (2021)

Impact of Nausea and Vomiting on Quality of Life in Cancer Patients During Chemotherapy
por: Ballatori, Enzo, et al.
Publicado: (2003)

Improved prophylaxis of postoperative nausea vomiting: Palonosetron a novel antiemetic
por: Shetti, Akshaya N., et al.
Publicado: (2014)

Granisetron Versus Dexamethasone in Prophylaxis of Nausea and Vomiting After Laparoscopic Cholecystectomy
por: Hessami, Mohammad Ali, et al.
Publicado: (2012)

Erratum to: ‘Prophylaxis and management of postoperative nausea and vomiting in enhanced recovery protocols’
por: Gupta, Ruchir, et al.
Publicado: (2016)

Effect of Adding Midazolam to Dual Prophylaxis for Preventing Postoperative Nausea and Vomiting
por: Lee, Jiyoung, et al.
Publicado: (2021)

Prevention of chemotherapy-induced nausea and vomiting: focus on fosaprepitant
por: Olver, Ian N
Publicado: (2008)

Cannot write session to /tmp/vufind_sessions/sess_mdnl2j33viu3jr8pc0n3hvm9lo